Thyroid Gland Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication (Hypothyroidism, Hyperthyroidism), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Wholesaler/Distributors, Retail Chain, Online Distribution, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.93 Billion
CAGR (2026-2031)	4.29%
Fastest Growing Segment	Oral
Largest Market	North America
Market Size (2031)	USD 3.77 Billion

Market Overview

The Global Thyroid Gland Disorder Treatment Market will grow from USD 2.93 Billion in 2025 to USD 3.77 Billion by 2031 at a 4.29% CAGR. The Global Thyroid Gland Disorder Treatment Market encompasses pharmaceutical interventions and therapies, such as levothyroxine and radioactive iodine, intended to restore hormonal balance in patients with hypothyroidism, hyperthyroidism, or thyroid cancer. The market is primarily driven by the escalating global prevalence of thyroid dysfunction and an aging population that necessitates sustained disease management. According to the American Cancer Society, in 2025, approximately 44,020 new cases of thyroid cancer are estimated to occur in the United States. This substantial patient burden underscores the critical need for consistent therapeutic supply and fuels the demand for effective treatment options across international healthcare sectors.

Nevertheless, the industry faces a significant challenge regarding the rigorous regulatory frameworks required for the approval of new therapeutics. Stringent compliance mandates and extensive safety validation for novel drug formulations often extend development timelines and increase operational costs. These regulatory barriers effectively slow the speed at which innovative treatments enter the commercial landscape and can impede market expansion in emerging economies with developing healthcare infrastructure.

Key Market Drivers

The Escalating Global Prevalence of Thyroid Disorders acts as the primary catalyst for market expansion, necessitating a consistent supply of hormone replacement therapies. As hypothyroidism rates climb due to aging populations and improved diagnostic detection, the dependency on standard-of-care treatments like levothyroxine continues to intensify. This sustained patient demand drives significant commercial volume for established pharmaceutical players, ensuring steady revenue growth in the chronic care segment. For instance, according to Merck Group, November 2025, in the 'Q3 2025: Merck Shows Solid Organic Growth Across All Sectors' report, the company's key thyroid medicine Euthyrox delivered organic net sales growth of 9.6%, supported by strong global demand. This substantial burden is further evidenced by prescription volumes in major healthcare systems; according to the U.S. Food and Drug Administration (FDA), August 2025, in the press release 'FDA's Actions to Address Unapproved Thyroid Medications', an estimated 22 million patients received prescriptions for levothyroxine in the United States alone during 2024.

Simultaneously, the Increasing Adoption of Novel Drug Formulations is diversifying revenue streams beyond generic hormone replacement. Pharmaceutical developers are strategically investing in biologics and targeted therapies to address complex comorbidities such as Thyroid Eye Disease (TED) and refractory thyroid cancers. These advancements offer high-value alternatives to traditional treatments, capturing significant market share through improved clinical outcomes and premium pricing structures. According to Amgen Inc., November 2025, in the 'Amgen Reports Third Quarter 2025 Financial Results', worldwide sales of Tepezza, a targeted therapy for thyroid eye disease, increased 15% year-over-year to reach $560 million for the quarter. This surge in adoption underscores a critical industry pivot toward specialized therapeutics that address specific, unmet needs within the broader thyroid disorder spectrum.

Download Free Sample Report

Key Market Challenges

The implementation of rigorous regulatory frameworks stands as a primary challenge obstructing the expansion of the Global Thyroid Gland Disorder Treatment Market. Pharmaceutical developers must navigate complex compliance mandates and conduct exhaustive clinical trials to validate the safety and efficacy of new therapeutics. These stringent requirements significantly inflate operational costs and extend the development timeline, creating a bottleneck that delays the commercial launch of innovative drug formulations. Consequently, the market is unable to rapidly respond to the evolving needs of healthcare providers and patients, leading to missed revenue opportunities and slower industry progression.

The impact of these regulatory delays is magnified by the substantial existing disease burden that requires timely and effective management. According to the American Thyroid Association, in 2025, an estimated 20 million Americans have some form of thyroid disease. This high volume of patients highlights the critical gap between the urgent demand for advanced treatments and the slow rate of product approval. By restricting the speed at which new therapies enter the market, regulatory barriers directly limit the industry's ability to serve this vast demographic, thereby stalling overall market growth.

Key Market Trends

The Integration of AI-Powered Diagnostic and Monitoring Solutions is significantly transforming the clinical management of thyroid nodules by enhancing imaging accuracy and workflow efficiency. Manufacturers are aggressively embedding deep learning algorithms directly into ultrasound platforms to assist radiologists in detecting, segmenting, and classifying thyroid lesions with greater consistency. This technological advancement addresses the subjectivity inherent in traditional manual examinations, thereby standardizing risk assessment protocols and potentially reducing the frequency of unnecessary biopsies for benign nodules. According to Samsung Medison, November 2025, in the press release 'Samsung Introduces R20 Ultrasound System, Elevating Imaging Performance and Precision at RSNA 2025', the company's newly launched R20 system integrates more than a dozen AI-powered tools specifically designed to automate measurements and provide real-time diagnostic guidance for complex cases.

Simultaneously, the Expansion of Targeted Tyrosine Kinase Inhibitors for Thyroid Cancer is reshaping the therapeutic landscape for patients with radioactive iodine-refractory disease. As understanding of the molecular drivers of thyroid malignancy deepens, the market is witnessing a surge in the commercial adoption of precision oncology therapies that inhibit specific pathways such as VEGFR and RET. This shift toward molecularly targeted treatments is driving substantial revenue growth for pharmaceutical developers as these oral therapies become standard-of-care alternatives to conventional chemotherapy. According to Exelixis Inc., May 2025, in the 'Exelixis Announces First Quarter 2025 Financial Results', the company's leading tyrosine kinase inhibitor, Cabometyx, generated net product revenues of $513.3 million for the quarter, supported by accelerating demand across its oncology indications including differentiated thyroid cancer.

Segmental Insights

The oral segment is anticipated to witness the most rapid expansion within the global thyroid gland disorder treatment market, primarily due to the high preference for non-invasive therapeutic options. Since thyroid pathologies generally require lifelong medication, the oral route facilitates easier self-administration and ensures better patient compliance than intravenous alternatives. This growth is further sustained by the frequent commercialization of improved oral formulations authorized by regulatory agencies such as the U.S. Food and Drug Administration. Consequently, the practicality and accessibility of oral dosages continue to drive their accelerated adoption among the growing patient population requiring chronic disease management.

Regional Insights

North America maintains a dominant position in the global thyroid gland disorder treatment market, driven by a well-established healthcare infrastructure and a rising prevalence of thyroid conditions. The region benefits significantly from the concentrated presence of key pharmaceutical manufacturers and comprehensive health insurance coverage that improves medication accessibility. Additionally, supportive regulatory frameworks provided by agencies like the U.S. Food and Drug Administration facilitate the timely approval and commercialization of new therapeutics. These factors, combined with elevated disease awareness and diagnostic rates, solidify North America's leading standing in the industry.

Recent Developments

• In January 2025, Sling Therapeutics announced positive topline efficacy and safety data from its Phase 2b/3 LIDS clinical trial evaluating linsitinib for the treatment of active, moderate-to-severe thyroid eye disease. The company reported that the investigational oral small molecule met its primary endpoint, demonstrating a statistically significant reduction in proptosis compared to a placebo at the 24-week mark. The study highlighted linsitinib as a potential convenient, twice-daily oral therapeutic option for patients, distinct from existing infusion-based biological treatments. Sling Therapeutics indicated that these results would support a confirmatory Phase 3 registrational trial scheduled to commence later in the year.
• In December 2024, Viridian Therapeutics reported positive topline results from its Phase 3 THRIVE-2 clinical trial evaluating veligrotug in patients with chronic thyroid eye disease. The study met all primary and secondary endpoints, with the investigational intravenous antibody demonstrating a statistically significant proptosis responder rate compared to the placebo. The company noted that the drug achieved rapid and meaningful improvements in eye bulging and diplopia with a favorable safety profile. These findings, combined with data from the earlier active disease trial, positioned the company to plan a Biologics License Application submission to regulatory authorities.
• In September 2024, Amgen received approval from Japan's Ministry of Health, Labour and Welfare for Tepezza (teprotumumab) for the treatment of active thyroid eye disease. This regulatory decision marked the first approval of the insulin-like growth factor-1 receptor inhibitor in Asia, providing a new non-surgical therapeutic option for patients in the region. The approval was supported by data from the Phase 3 OPTIC-J clinical trial, which demonstrated that a significant majority of treated patients achieved a clinically meaningful reduction in proptosis compared to those receiving a placebo. Amgen highlighted this milestone as a significant expansion of its global footprint in the thyroid gland disorder treatment market.
• In June 2024, Eli Lilly and Company obtained traditional approval from the U.S. Food and Drug Administration for Retevmo (selpercatinib) for the treatment of adult and pediatric patients two years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. The regulatory agency granted this approval based on robust efficacy data, including durable response rates, from the LIBRETTO-001 clinical trial. This action converted the drug's previous accelerated approval into a full approval for this specific indication, solidifying its role as a standard systemic therapy for patients with this genetic alteration who require treatment and are radioactive iodine-refractory.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• GSK Plc
• Merck KGaA
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Elexis Inc.
• IBSA Group

By Indication	By Route of Administration	By Distribution Channel	By Region
Hypothyroidism Hyperthyroidism	Oral Intravenous Others	Wholesaler/Distributors Retail Chain Online Distribution Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Thyroid Gland Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Thyroid Gland Disorder Treatment Market, By Indication:

• Hypothyroidism
• Hyperthyroidism

• Thyroid Gland Disorder Treatment Market, By Route of Administration:

• Oral
• Intravenous
• Others

• Thyroid Gland Disorder Treatment Market, By Distribution Channel:

• Wholesaler/Distributors
• Retail Chain
• Online Distribution
• Others

• Thyroid Gland Disorder Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE